Data Sheet 1_Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study.pdf

Data Sheet 1_Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study.pdf

Background<p>Target-specific immunotherapies have been shown to effectively treat myasthenia gravis (MG) with less side effects. One such immunotherapy is efgartigimod, a neonatal Fc receptor antagonist, promotes degradation of pathogenic IgG antibodies. However, data specifically focusing on...

Full description

Saved in:
Bibliographic Details
Main Author: Ye Hong (2580841) (author)
Other Authors: Chang-Wen Yuan (22571810) (author), Jie Lu (139953) (author), Ping-Ping Kong (22571813) (author), Shi-Qi Huang (6542189) (author), Rui-Yuan Yang (10763914) (author), Zhen-Hua Yuan (20830253) (author), Hong-Dong Zhao (20830259) (author), Teng Jiang (131520) (author), Jing Chen (4762) (author), Jian-Quan Shi (20830250) (author)
Published: 2025
Subjects:
Genetic Immunology
myasthenia gravis
efgartigimod
elderly
VLOMG
MG-ADL
MGAE
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items